Our state of the art laboratory located in Stratford-upon-Avon includes the infrastructure required for the pre-clinical development of the Company’s portfolio of antibodies, oligonucleotides and cell and gene therapies. The siRNA and MK therapeutics were developed in this secure and dedicated facility built in 2017, encompassing over 5,000 sq. ft of co-located laboratory and office space designed for biotechnology, by Professor Sir Martin Evans and his team.
The facility includes the clean room, laminar flow cabinets and cryopreservation infrastructure required for pre-clinical development of innovative new medicines particularly cell and gene therapies. During the pandemic the facilities were utilised for the development and clinical trials of novel medical diagnostics.
GMP Manufacturing Facility
Roquefort Therapeutics has access to a GMP manufacturing facility designed for the manufacture of biological (cell and antibody) candidate medicines. The EU facility has successfully manufactured products for US, EU and UK approved clinical trials and includes state-of-the art clean room laboratories with laminar flow cabinets, cryo-preservation and on-site quality control laboratory. Utilisation of this facility for the pharmacological manufacturing development of the portfolio of antibodies, oligonucleotides, cell and gene therapies and potential manufacture for clinical trials can provide a significant strategic cost and time advantage to the Company.